Globally, More than 100+ Key Companies are working in the Atopic Dermatitis Pipeline Landscape

Globally, More than 100+ Key Companies are working in the Atopic Dermatitis Pipeline Landscape

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


The Atopic Dermatitis pipeline report also provides the inactive products analysis (dormant and terminated) along with the reasons for dormancy and discontinuation, wherever available. This report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products.


Atopic Dermatitis Overview

Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, “weeping” clear fluid, crusting, and scaling.


Download a PDF Sample Report-


Atopic Dermatitis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights about companies that are developing therapies in the Atopic Dermatitis
  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis
  • Atopic Dermatitis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atopic Dermatitis Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis

The report is built using data and information traced from the researcher proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Atopic Dermatitis Emerging Drugs

  • Amlitelimab: Kymab
  • BX 005: BiomX
  • LP 0145: LEO Pharma


Atopic Dermatitis Pipeline Therapeutic Analysis

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.


Atopic Dermatitis Pipeline Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Atopic Dermatitis Pipeline Companies

  • Kymab
  • BiomX
  • LEO Pharma
  • GlaxoSmithKline
  • Arjil Pharmaceuticals
  • SCM Lifescience
  • Sun Pharmaceutical Industries Limited
  • Brickell Biotech Inc
  • Dermira
  • AstraZeneca
  • Kyowa Kirin
  • UCB Biopharma
  • Arcutis Biotherapeutics, and several others


Atopic Dermatitis Pipeline Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule


Atopic Dermatitis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.


Atopic Dermatitis Emerging Drugs Chapters

This segment of the Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Request a PDF Sample Report-


Table of Content

  1. Introduction
  2. Executive Summary
  3. Atopic Dermatitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Mid Stage Products (Phase II)
  10. Amlitelimab: Kymab
  11. Early Stage Products (Phase I/II)
  12. Drug name: Company name
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Atopic Dermatitis Key Companies
  17. Atopic Dermatitis Key Products
  18. Atopic Dermatitis- Unmet Needs
  19. Atopic Dermatitis- Market Drivers and Barriers
  20. Atopic Dermatitis- Future Perspectives and Conclusion
  21. Atopic Dermatitis Analyst Views
  22. Atopic Dermatitis Key Companies
  23. Appendix


Do you have any query related to the report? If yes, click here-

Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States